Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen–Results of a Real-Life Study From a Middle-Income Country

Imagem de Miniatura
Arquivos
art_LAGE_Upfront_Therapy_With_CHOP_Plus_Etoposide_in_Brazilian_2022.PDF (782.3 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER INC.
Autores
BRITO, C. V.
COSTA, R. D. O.
Citação
CLINICAL LYMPHOMA, MYELOMA AND LEUKEMIA, v.22, n.11, p.812-824, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Nodal peripheral T-cell lymphoma (nPTCL) constitute a heterogeneous group of neoplasms with aggressive behavior and poor-survival. They are more prevalent in Latin America and Asia, although data from Brazil are scarce. Its primary therapy is still controversial and ineffective. Therefore, we aim to describe clinical-epidemiological characteristics, outcomes, predictors factors for survival and compare the results of patients treated with CHOP and CHOEP regimens. Methods: Retrospective, observational and single-center study involving 124 nPTCL patients from Brazil treated from 2000 to 2019. Results: With a median follow-up of 23.7 months, the estimated 2-year overall survival (OS) and progression-free survival (PFS) were 59.2% and 37.3%, respectively. The median age was 48.5 years and 57.3% (71/124) were male, 81.5% (101/124) had B-symptoms, 88.7% (110/124) had advanced disease (stage III/IV) and 58.1% (72/124) presented International Prognostic Index (IPI) score ≥3, reflecting a real-life cohort. ORR to first-line therapy was 58.9%, 37.9% (N = 47) received CHOP-21 and 35.5% (N = 44) were treated with CHOEP-21; 30.1% (37/124) underwent to consolidation with involved field radiotherapy (IF-RT) and 32.3% (40/124) were consolidated with autologous hematopoietic stem cell transplantation (ASCT). The overall response rate (ORR) was similar for CHOP-21 (76.6%) and CHOEP-21 (65.9%), P =.259. Refractory disease was less frequent in the CHOEP-21 group (4.5% vs. 21.2%, P =.018). However, few patients were able to complete 6-cycles of CHOEP-21 (31.8%) than to CHOP-21 (61.7%), P =.003. Delays ≥2 weeks among the cycles of chemotherapy were more frequent for patients receiving CHOEP-21 (43.1% vs. 10.6%), P =.0004, as well as the toxicities, including G3-4 neutropenia (88% vs. 57%, P =.001), febrile neutropenia (70% vs. 38%, P =.003) and G3-4 thrombocytopenia (63% vs. 27%, P =.0007). The 2-year OS was higher for CHOP (78.7%) than CHOEP group (61.4%), P =.05, as well as 2-year PFS (69.7% vs. 25.0%, P <.0001). In multivariate analysis, high LDH (HR 3.38, P =.007) was associated with decreased OS. CR at first line (HR: 0.09, P <.001) and consolidation with ASCT (HR: 0.08, P =.015) were predictors of increased OS. Conclusion: In the largest cohort of nPTCL from Latin America, patients had poor survival and high rate of chemo-resistance. In our cohort, the addition of etoposide to the CHOP-21 backbone showed no survival benefit and was associated with high-toxicity and frequent treatment interruptions. Normal LDH values, obtaintion of CR and consolidation with ASCT were independent factors associated with better outcomes. © 2022 Elsevier Inc.
Palavras-chave
Middle-income regions, Nodal peripheral T-cell lymphoma (nPTCL), Outcomes, Prognostic factors, Treatment
URI
https://observatorio.fm.usp.br/handle/OPI/55910
Referências
  1. Swerdlow S.H., Campo E., Pileri S.A., Et al., The 2016 revision of the World Health Organization classification of lymphoid neoplasms, Blood, 127, pp. 2375-2390, (2016)
  2. Lage L.A.P.C., Cabral T.C.S., Costa R.O., Et al., Primary nodal peripheral T-cell lymphoma: diagnosis and therapeutic considerations, Rev Bras Hematol Hemoter, 37, pp. 277-284, (2015)
  3. Vose J., Armitage J., Weisenburger D., International peripheral T-cell and natural-killer/T-cell lymphoma study: pathology findings and clinical outcomes, J Clin Oncol, 26, pp. 4124-4130, (2008)
  4. Siaghani P.J., Wong J.T., Chan J., Weisenburger D., Song J.Y., Epidemiology and pathology of T- and NK-cell lymphomas, Cancer Treat Res, 176, pp. 1-29, (2019)
  5. Charton-Bain M.C., Brousset P., Bouabdallah R., Et al., Variation in the histological pattern of nodal involvement by gamma/delta T-cell lymphoma, Histopathology, 36, pp. 233-239, (2000)
  6. Saito T., Matsuno Y., Tanosaki R., Watanabe T., Kobayashi Y., Tobinai K., Gamma delta T-cell neoplasms: a clinopathological study of 11 cases, Ann Oncol, 13, pp. 1792-1798, (2002)
  7. Kagami Y., Nakamura S., Suzuki R., Et al., A nodal gamma/delta T-cell lymphoma with an association of Epstein-Barr virus, Am J Surg Pathol, 21, pp. 729-736, (1997)
  8. Petrich A.M., Helenowski I.B., Bryan L.J., Rozell S.A., Galamaga R., Nabhan C., Factors predicting survival in peripheral T-cell lymphoma in the USA: a population-based analysis of 8802 patients in the modern era, Br J Haematol, 168, pp. 708-718, (2015)
  9. Ferreira C.R., Manohar V., Zhao S., Et al., Genetic subtypes of systemic anaplastic large cell lymphoma show distinct differences in PD-L1 expression and regulatory and cytotoxic T-cells in the tumor microenvironment, Appl Immunohist Mol Morphol, 28, pp. 10-16, (2020)
  10. Lage L.A.P.C., Hamasaki D.T., Moreira F.R., Rocha V., Zerbini M.C.N., Pereira J., Absolute monocyte count is a predictor of overall survival and progression-free survival in nodal peripheral T-cell lymphoma, Ann Hematol, 98, pp. 2097-2102, (2019)
  11. Lage L.A.P.C., Levy D., Xavier F.D., Et al., Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma, Oncotarget, 10, pp. 5136-5151, (2019)
  12. Lage L.A.P.C., Brito C.V., Levy D., Et al., Diagnostic and prognostic implications of tumor expression of the GATA-3 gene in nodal peripheral T-cell lymphoma (nPTCL): retrospective data from a Latin American cohort, Leuk Res, 114, pp. 106794-106802, (2022)
  13. Dearden C.E., Johnson R., Pettengell R., Et al., Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphomas), Br J Haematol, 153, pp. 451-485, (2011)
  14. Armitage J.O., The aggressive peripheral T-cell lymphomas: 2017, Am J Hematol, 92, pp. 706-715, (2017)
  15. Fiore D., Cappelli L.V., Broccoli A., Zinzani P.L., Chan W.C., Inghirami G., Peripheral T-cell lymphomas: from the bench to the clinic, Nat Rev Cancer, 20, pp. 323-342, (2020)
  16. Wudhikarn K., Bunworasate U., Julamanee J., Et al., Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T-cell lymphoma, Hematol Oncol, 37, pp. 578-585, (2019)
  17. Wudhikarn K., Bunworasate U., Julamanee J., Et al., Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T-cell lymphoma and natural-killer/T cell non-Hodgkin lymphoma in older patients: the result of the nationwide multi-institutional registry Thai Lymphoma Study Group, J Geriatr Oncol, 11, pp. 62-68, (2020)
  18. Kansara R., Savage K.J., The problem with cyclophosphamide, doxorubicin, vincristine and prednisone for the treatment of peripheral T-cell lymphoma, Leuk Lymphoma, 55, pp. 727-729, (2014)
  19. Deng S., Lin S., Shen J., Zeng Y., Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: a meta-analysis, Onco Targets Ther, 12, pp. 2335-2342, (2019)
  20. Cheson B.D., Fisher R.I., Barrington S.F., Et al., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification, J Clin Oncol, 32, pp. 3059-3068, (2014)
  21. Savage K.J., Harris N.L., Vose J.M., Et al., ALK-negative anaplastic large cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project, Blood, 111, pp. 5496-5504, (2008)
  22. Mahadevan D., List A.F., Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies, Blood, 104, pp. 1940-1951, (2004)
  23. Heavican T.B., Bouska A., Yu J., Et al., Genetic drivers of oncogenic pathway in molecular subgroups of peripheral T-cell lymphoma, Blood, 133, pp. 1664-1676, (2019)
  24. Ye Y., Ding N., Mi L., Et al., Correlation of mutational landscape and survival outcome of peripheral T-cell lymphoma, Exp Hematol Oncol, 10, (2021)
  25. Watatani Y., Sato Y., Miyoshi H., Et al., Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling, Leukemia, 33, pp. 2867-2883, (2019)
  26. Garcia M.J., Martinez-Delgado B., Cebrian A., Martinez A., Benitez J., Rivas C., Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin's and CD30-positive non-Hodgkin's lymphomas, Am J Pathol, 161, pp. 1007-1013, (2002)
  27. Gallamini A., Zaja F., Pitti C., Et al., Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial, Blood, 110, pp. 2316-2323, (2007)
  28. Foss F.M., Sjak-Shie N., Goy A., Et al., A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin-diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study, Leuk Lymphoma, 54, pp. 1373-1379, (2013)
  29. Ganjoo K., Hong F., Horning S.J., Et al., Bevacizumab and cyclophosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell and natural killer cell neoplasms: an Eastern Cooperative Oncology Group Study (E2404), Leuk Lymphoma, 55, pp. 768-772, (2014)
  30. Mahadevan D., Unger J.M., Spier C.M., Et al., Phase 2 trial of combined cisplatin, etopoide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350, Cancer, 119, pp. 371-379, (2013)
  31. Pro B., Advani R., Brice P., Et al., Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study, J Clin Oncol, 30, pp. 2190-2196, (2012)
  32. Horwitz S., O'Connor O.A., Pro B., Et al., The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma, Ann Oncol, (2021)
  33. Savage K.J., Horwitz S.M., Advani R.H., Et al., An exploratory analysis of brentuximab-vedotin plus CHP (A+CHP) in the frontline treatment of patients with CD30+ peripheral T-cell lymphoma (ECHELON-2): impact of consolidative stem cell transplant, Blood, 134, (2019)
  34. Schmitz N., Trumper L., Ziepert M., Et al., Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of German High-Grade Non-Hodgkin Lymphoma Study Group, Blood, 116, pp. 3418-3425, (2010)
  35. Ellin F., Landstrom J., Jerkerman M., Relander T., Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry, Blood, 124, pp. 1570-1577, (2014)
  36. Liu X., Yang M., Wu M., Et al., A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas, Cancer Chemother Pharmacol, 83, pp. 443-449, (2019)
  37. Kim J., Cho J., Byeon S., Kim W.S., Kim S.J., Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: a systematic review and meta-analysis, Hematol Oncol, 39, pp. 664-673, (2021)
  38. Sehn L.H., Congiu A.G., Culligan D.J., Et al., No added benefit of eight versus six cycles of CHOP when combined with rituximab in previously untreated diffuse large B-cell lymphoma patients: results from the international phase III GOYA study, Blood, 132, (2018)
  39. Wang C., McKheitan T.W., Gong Q., Et al., IDH2 R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma, Blood, 126, pp. 1741-1752, (2015)
  40. Lemonnier F., Couronne L., Parrens M., Et al., Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with THF- like features and adverse clinical parameters, Blood, 120, pp. 1466-1469, (2012)
  41. Couronne L., Bastard C., Bernard O.A., TET2 and DNMT3A mutations in human T-cell lymphoma, N Engl J Med, 366, pp. 95-96, (2012)
  42. Liu M.K., Sun X.J., Gao X.D., Qian D., Wang L., Zhao W.L., Methylation alterations and advance of treatment in lymphoma, Front Biosci, 26, pp. 602-613, (2021)
  43. Falchi L., Ma H., Klein S., Et al., Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study, Blood, 137, pp. 2161-2170, (2021)
  44. Reimer P., Rudiger T., Geissinger E., Et al., Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter trial, J Clin Oncol, 27, pp. 105-113, (2009)
  45. d'Amore F., Relander T., Lauritzsen G.F., Et al., Up-front autologous stem cell transplantation in peripheral T-cell lymphoma: NLG-T-01, J Clin Oncol, 30, pp. 3093-3099, (2012)
  46. Chen Z., Huang H., Li X., Fang X., Wang Z., Hong H., Et al., Chemotherapy plus radiotherapy versus chemotherapy alone for patients with peripheral T-cell lymphoma, not otherwise specified, Front Oncol, 11, (2021)
  47. Advani R.H., Skrypets T., Civallero M., Et al., Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project, Blood, 138, pp. 213-220, (2021)
  48. Lemonnier F., Dupuis J., Sujobert P., Et al., Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma, Blood, 132, pp. 2305-2309, (2018)
  49. O'Connor O.A., Horwitz S., Masszi T., Et al., Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study, J Clin Oncol, 33, pp. 2492-2499, (2015)
  50. Ma H., Davarifar A., Amengual J.E., The future of combination therapies for peripheral T cell lymphomas (PTCL), Curr Hematol Malig Rep, 13, pp. 13-24, (2018)
  51. Fallini B., Pileri S., Zinzani P.L., Et al., ALK+ lymphoma: clinic-pathological findings and outcomes, Blood, 93, pp. 2697-2706, (1999)
  52. Suzuki R., Kagami Y., Takeuchi K., Et al., Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype, Blood, 96, pp. 2993-3000, (2000)
  53. Sibon D., Nguyen D.P., Schmitz N., Et al., ALK-positive anaplastic large-cell lymphoma in adults: an individual patient data pooled analysis of 263 patients, Haematologica, 104, pp. e562-e565, (2019)
  54. Sibon D., Fournier M., Briere J., Et al., Long-term outcome of adults with anaplastic large-cell lymphoma treated within the Gruope d´Etude des Lymphomes de l´adulte trials, J Clin Oncol, 30, pp. 3939-3946, (2012)
  55. Feldman A.L., Dogan A., Smith D.I., Et al., Discovery of recurrent t(6;7)(p25.3;q32.3) translocation in ALK-negative anaplastic large-cell lymphomas by massively parallel genomic sequencing, Blood, 117, pp. 915-919, (2011)
  56. Castellar E.R.P., Jaffe E.S., Said J.W., Et al., ALK-negative anaplastic large-cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes, Blood, 124, pp. 1473-1490, (2014)

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/19
Carregar mais